Now with ac­tu­al da­ta in hand, Cel­gene touts an ear­ly re­sponse for Crohn’s drug mon­gersen

A month af­ter post­ing an un­der­whelm­ing top-line as­sess­ment of a Phase Ib study of its close­ly watched Crohn’s drug mon­gersen (GED-0301) for Crohn’s dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.